Full Approval of Treatment Standard Forces Avrobio to Adjust Fabry Disease Therapy Plans
On May 3rd, Massachusetts-based Avrobio announced updated regulatory plans for AVR-RD-01, its investigational gene therapy candidate. The change is an outcome of the full approval received by Sanofi’s Fabrazyme, the …
Read More